Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 21
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,595
+24.78%
|
-
|
|
Feb 21
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Grant, award, or other acquisition
|
Direct |
34,387
+37.34%
|
-
|
|
Feb 21
2022
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
85,971
+36.85%
|
-
|
|
Feb 21
2022
|
Karen S Lynch President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
257,916
+44.09%
|
-
|
|
Feb 21
2022
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
787,472
+34.19%
|
-
|
|
Feb 21
2022
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
322,395
+43.08%
|
-
|
|
Feb 21
2022
|
Prem S Shah EVP and Group President |
BUY
Grant, award, or other acquisition
|
Direct |
47,640
+44.42%
|
-
|
|
Feb 10
2022
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
1,000
+5.17%
|
$105,000
$105.9 P/Share
|
|
Feb 03
2022
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
47,937
-25.75%
|
$5,273,070
$110.0 P/Share
|
|
Feb 03
2022
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,937
+20.48%
|
$4,889,574
$102.26 P/Share
|
|
Feb 01
2022
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
21,386
-25.85%
|
$2,266,916
$106.5 P/Share
|
|
Feb 01
2022
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Exercise of conversion of derivative security
|
Direct |
21,386
+20.54%
|
$2,181,372
$102.26 P/Share
|
|
Jan 28
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
6,059
-25.72%
|
$660,431
$109.0 P/Share
|
|
Jan 28
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,059
+20.46%
|
$618,018
$102.26 P/Share
|
|
Jan 27
2022
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
68,482
-39.0%
|
$7,327,574
$107.5 P/Share
|
|
Jan 27
2022
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,482
+28.06%
|
$6,985,164
$102.26 P/Share
|
|
Dec 27
2021
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
200
-3.32%
|
$17,600
$88.78 P/Share
|
|
Dec 01
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
68
-0.4%
|
$5,984
$88.78 P/Share
|
|
Nov 28
2021
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,121
-16.97%
|
$1,285,011
$91.52 P/Share
|
|
Nov 17
2021
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,314
+3.36%
|
$120,888
$92.73 P/Share
|
|
Nov 17
2021
|
Mary L Schapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
417
+5.21%
|
$38,364
$92.73 P/Share
|
|
Nov 17
2021
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,253
+50.0%
|
$115,276
$92.73 P/Share
|
|
Nov 17
2021
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,314
+50.0%
|
$120,888
$92.73 P/Share
|
|
Nov 17
2021
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,154
+2.79%
|
$290,168
$92.73 P/Share
|
|
Nov 17
2021
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,334
+5.39%
|
$122,728
$92.73 P/Share
|
|
Nov 17
2021
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,253
+4.56%
|
$115,276
$92.73 P/Share
|
|
Nov 03
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
108,870
-50.41%
|
$10,342,650
$95.0 P/Share
|
|
Nov 03
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
108,870
+33.51%
|
$4,899,150
$45.93 P/Share
|
|
Nov 01
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
28,159
-16.92%
|
$2,534,310
$90.0 P/Share
|
|
Nov 01
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,159
+14.47%
|
$1,633,222
$58.34 P/Share
|
|
Oct 26
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
82,757
-18.89%
|
$7,282,616
$88.0 P/Share
|
|
Oct 26
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
80,802
+26.77%
|
$4,363,308
$54.19 P/Share
|
|
Sep 02
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,625
-1.84%
|
$228,375
$87.0 P/Share
|
|
Aug 05
2021
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
3,000
+14.75%
|
$237,000
$79.55 P/Share
|
|
Jun 28
2021
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
2,781
-4.36%
|
$230,823
$83.67 P/Share
|
|
Jun 15
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
67,552
-32.11%
|
$5,809,472
$86.0 P/Share
|
|
Jun 15
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
65,681
+23.79%
|
$4,072,222
$62.21 P/Share
|
|
Jun 07
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Open market or private sale
|
Direct |
37,594
-61.73%
|
$3,233,084
$86.6 P/Share
|
|
Jun 07
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Exercise of conversion of derivative security
|
Direct |
32,320
+34.67%
|
$1,745,280
$54.19 P/Share
|
|
May 31
2021
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-0.1%
|
$54,524
$86.44 P/Share
|
|
May 28
2021
|
Shawn M Guertin EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,706
+50.0%
|
$2,984,716
$86.44 P/Share
|
|
May 13
2021
|
Mary L Schapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
459
+6.02%
|
$38,556
$84.27 P/Share
|
|
May 13
2021
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,379
+5.23%
|
$115,836
$84.27 P/Share
|
|
May 13
2021
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,468
+6.24%
|
$123,312
$84.27 P/Share
|
|
May 13
2021
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,470
+3.15%
|
$291,480
$84.27 P/Share
|
|
May 13
2021
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,446
+50.0%
|
$121,464
$84.27 P/Share
|
|
May 13
2021
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,379
+50.0%
|
$115,836
$84.27 P/Share
|
|
May 13
2021
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,446
+3.81%
|
$121,464
$84.27 P/Share
|
|
May 10
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
109,469
-100.0%
|
$9,414,334
$86.0 P/Share
|
|
May 10
2021
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
109,469
+50.0%
|
$6,787,078
$62.21 P/Share
|